ABL Bio has developed its Grabody-B platform to target the insulin-like growth factor 1 receptor (IGF1R) in order to help transport drugs for neurodegenerative disease over the notoriously tricky ...

Single-point mutations within the kinase domain of BCR–ABL constitute the most frequent cause of acquired resistance to ABL kinase inhibitors in patients with chronic myeloid leukaemia (CML ...

In chronic myelogenous leukaemia (CML), a reciprocal translocation between chromosomes 9 and 22 results in a gene encoding BCR–ABL, a fused deregulated kinase that stimulates cellular ...

GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases. The global licensing deal will allow GSK to use ABL Bio’s blood-brain barrier (BBB) ...

SEONGNAM, South Korea, April 6, 2025 /PRNewswire/ -- ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and ...